Curcumin Compositions and Uses as NK3 Antagonists

Curcumin and green tea extract compositions, combined with phycocyanin, serve as NK3 receptor antagonists to address the lack of effective treatments for menopausal symptoms by blocking relevant signaling pathways, effectively reducing LH and FSH secretion.

JP2024544541AInactive Publication Date: 2024-12-03BONAFIDE HEALTH LLC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024527646
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-12
Filing Date
2022-10-18
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a lack of effective neurokinin 3 (NK3) receptor antagonists to alleviate menopausal symptoms such as hot flashes and night sweats, as conventional methods have failed to develop potent and selective antagonists.

Method used

Development of curcumin, green tea extract, and phycocyanin compositions, formulated alone or in combination, to act as NK3 receptor antagonists, providing therapeutic and nutritional benefits.

Benefits of technology

The compositions effectively reduce menopausal symptoms by targeting signaling pathways associated with menopause, specifically by blocking kisspeptin and NKB signaling, thereby reducing LH and FSH secretion.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544541000001_ABST
    Figure 2024544541000001_ABST
Patent Text Reader

Abstract

Disclosed herein are compositions for treating, ameliorating, preventing or alleviating menopausal-related symptoms and / or hot flashes. The compositions disclosed herein include a curcumin composition, a green tea extract composition and a phycocyanin composition, which act as neurokinin 3 receptor antagonists. Methods of utilizing the compositions are also described herein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] background Neurokinin 3 (NK3) receptors are primarily expressed in the central nervous system and are the most selective of the tachykinin receptors, being bound and activated very preferentially by its endogenous ligand, neurokinin-B (NKB). Compared to the neurokinin-1 (NK1) and neurokinin-2 (NK2) receptors, the study of the NK3 receptor has received little attention, mainly due to the lack of potent and selective non-peptidic NK3 receptor antagonists. The inventors have revealed the relationship between NK3 receptor agonists and menopausal symptoms, including hot flashes and night sweats, and have recognized the high demand for the development of novel NK3 receptor antagonists. NK3 receptor antagonists are believed to alleviate such symptoms. Although NK3 receptor antagonists are believed to provide many potential benefits to subjects, the development of effective antagonists has not been possible for conventional scientists. Thus, there is a need to develop and provide NK3 antagonists. By providing NK3 antagonists as pharmaceuticals and / or dietary supplements, therapeutic and nutritional benefits can be achieved individually, jointly, or in combination with other pharmaceuticals and / or dietary supplements. Summary of the Invention

[0002] Aspects of the present disclosure relate to novel NK3 receptor antagonists and their use in ameliorating and / or treating menopausal or associated symptoms.

[0003] These and other features, aspects, and advantages of the present embodiments will become apparent with reference to the following description, claims, and drawings. [Brief description of the drawings]

[0004] [Figure 1A] FIG. 1A shows a dose-response curve of a curcumin composition described herein administered to transfected Chinese Hamster Ovary (CHO) cells in vitro. [Figure 1B]FIG. 1B shows a dose response curve of a green tea extract composition described herein administered to transfected Chinese Hamster Ovary (CHO) cells in vitro. [Figure 1C] FIG. 1C shows a dose-response curve of the phycocyanin compositions described herein administered to transfected Chinese hamster ovary (CHO) cells in vitro. [Diagram 2] Figure 2 shows the results of administering the curcumin composition, green tea extract composition and phycocyanin composition, and their combinations, to female Wistar rats in vivo. Figure 2 shows hypothalamic levels of NKB for non-ovariectomized female Wistar rats (C); ovariectomized female Wistar rats (OVX); ovariectomized female Wistar rats treated with the curcumin composition described in the specification at 600 mg human equivalent dose (HED) (OVX+CL); ovariectomized female Wistar rats treated with the green tea extract composition described in the specification at 300 mg HED (OVX+EGCG); ovariectomized female Wistar rats treated with the phycocyanin composition described in the specification at 100 mg HED (OVX+P); and ovariectomized female Wistar rats treated with the combination of the curcumin composition, green tea extract composition and phycocyanin composition disclosed in this specification at the above doses (OVX+CL+EGCG+P). Densitometric analysis of relative intensity of Western blot bands to controls was performed with β-actin normalization to ensure equal protein input. Blots were repeated at least three times (n=3) and representative blots are shown. Data are presented as mean ± standard deviation. Different lowercase letters (a-d) above the data columns indicate statistical differences between groups. [Diagram 3]FIG. 3 shows the in vivo results of administering to female Wistar rats combinations of the curcumin, green tea extract and phycocyanin compositions described herein, with varying doses of the curcumin and green tea extract compositions. FIG. 3 shows hypothalamic levels of NKB for non-ovariectomized female Wistar rats (C); ovariectomized female Wistar rats (OVX); ovariectomized female Wistar rats treated with a combination of 600 mg HED of a curcumin composition, 300 mg HED of a green tea extract composition, and 100 mg HED of a phycocyanin composition (OVX+CL1+EGCG1+P); ovariectomized female Wistar rats treated with a combination of 450 mg HED of a curcumin composition, 450 mg HED of a green tea extract composition, and 100 mg HED of a phycocyanin composition (OVX+CL2+EGCG2+P); and ovariectomized female Wistar rats treated with a combination of 720 mg HED of a curcumin composition, 180 mg HED of a green tea extract composition, and 100 mg HED of a phycocyanin composition (OVX+CL3+EGCG3+P). Densitometric analysis of the relative intensity of Western blot bands to controls was performed with β-actin normalization to ensure equal protein input. Blots were repeated at least three times (n=3) and representative blots are shown. Data are presented as mean ± standard deviation. Different lowercase letters (a-f) above the data columns indicate statistical differences between groups. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0005] Detailed Description Some embodiments provide compositions comprising one or more curcumin extracts formulated as a curcumin composition. In certain embodiments, the curcumin composition can comprise diferuloylmethane, demethoxycurcumin (DMC), bis-demethoxycurcumin (BDMC), tetrahydrocurcumin, dihydrocurcumin, hexahydrocurcumin, octahydrocurcumin, or any combination thereof. In some embodiments, the curcumin compositions described herein can comprise a pharma- ceutically acceptable vehicle, carrier, or diluent.

[0006] The structure of diferuloylmethane is shown below. [ka]

[0007] The structure of DMC is shown below. [ka]

[0008] The structure of BDMC is shown below. [ka]

[0009] The structure of tetrahydrocurcumin is shown below. [ka]

[0010] The structure of dihydrocurcumin is shown below. [ka]

[0011] The structure of hexahydrocurcumin is shown below. [ka]

[0012] The structure of octahydrocurcumin is shown below. [ka]

[0013] In some embodiments, the curcumin compositions described herein may include at least two of diferuloylmethane, DMC, BDMC, tetrahydrocurcumin, dihydrocurcumin, hexahydrocurcumin, and octahydrocurcumin. For example, the curcumin composition may include diferuloylmethane and DMC present in a ratio of about 1:1, or about 20:1 to about 1:20 of diferuloylmethane to DMC, or any ratio therebetween. In some embodiments, the curcumin composition may include diferuloylmethane and BDMC present in a ratio of about 1:1, or about 20:1 to about 1:20 of diferuloylmethane to BDMC, or any ratio therebetween. In certain embodiments, the curcumin composition may include diferuloylmethane and tetrahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of diferuloylmethane to tetrahydrocurcumin, or any ratio therebetween. In some embodiments, the curcumin composition can include diferuloylmethane and dihydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of diferuloylmethane to dihydrocurcumin, or any ratio therebetween. In certain embodiments, the curcumin composition can include diferuloylmethane and hexahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of diferuloylmethane to hexahydrocurcumin, or any ratio therebetween. In some embodiments, the curcumin composition can include diferuloylmethane and octahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of diferuloylmethane to octahydrocurcumin, or any ratio therebetween. In certain embodiments, the curcumin composition can include DMC and BDMC present in a ratio of about 1:1, or about 20:1 to about 1:20 of DMC to BDMC, or any ratio therebetween. In some embodiments, the curcumin composition can include DMC and tetrahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of DMC to tetrahydrocurcumin, or any ratio therebetween.In certain embodiments, the curcumin composition can include DMC and dihydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of DMC to dihydrocurcumin, or any ratio therebetween. In some embodiments, the curcumin composition can include DMC and hexahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of DMC to hexahydrocurcumin, or any ratio therebetween. In certain embodiments, the curcumin composition can include DMC and octahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of DMC to octahydrocurcumin, or any ratio therebetween. In some embodiments, the curcumin composition can include BDMC and tetrahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of BDMC to tetrahydrocurcumin, or any ratio therebetween. In certain embodiments, the curcumin composition can include BDMC and dihydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 BDMC to dihydrocurcumin, or any ratio therebetween. In some embodiments, the curcumin composition can include BDMC and hexahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 BDMC to hexahydrocurcumin, or any ratio therebetween. In certain embodiments, the curcumin composition can include BDMC and octahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 BDMC to octahydrocurcumin, or any ratio therebetween. In certain embodiments, the curcumin composition can include tetrahydrocurcumin and dihydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 BDMC to dihydrocurcumin, or any ratio therebetween. In some embodiments, the curcumin composition can include tetrahydrocurcumin and hexahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of tetrahydrocurcumin to hexahydrocurcumin, or any ratio therebetween.In certain embodiments, the curcumin composition can include tetrahydrocurcumin and octahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of tetrahydrocurcumin to octahydrocurcumin, or any ratio therebetween. In some embodiments, the curcumin composition can include dihydrocurcumin and hexahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of dihydrocurcumin to hexahydrocurcumin, or any ratio therebetween. In certain embodiments, the curcumin composition can include dihydrocurcumin and octahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of dihydrocurcumin to octahydrocurcumin, or any ratio therebetween. In certain embodiments, the curcumin composition can include hexahydrocurcumin and octahydrocurcumin present in a ratio of about 1:1, or about 20:1 to about 1:20 of hexahydrocurcumin to octahydrocurcumin, or any ratio therebetween. Additionally, any two of the above compounds can be present in a ratio of about 20:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:20, or any ratio therebetween. In view of the results and discussion contained herein, one of skill in the art would know how to formulate the curcumin compositions of the present disclosure to achieve the results described herein.

[0014] In certain embodiments, the curcumin compositions described herein may include three or more of diferuloylmethane, DMC, BDMC, tetrahydrocurcumin, dihydrocurcumin, hexahydrocurcumin, and octahydrocurcumin. The three or more compounds may be present in a ratio. Ratios may be understood to include "parts" of any compound. For example, a curcumin composition may include a 4:1:10 ratio of diferuloylmethane, DMC, and BDMC, which corresponds to 4 parts diferuloylmethane, 1 part DMC, and 10 parts BDMC. The individual amounts of any of the above compounds may be as low as 1 part, as high as 20 parts, or any value therebetween. In view of the results and discussion contained herein, one of skill in the art would understand how to formulate the curcumin compositions of the present disclosure to achieve the results described herein.

[0015] Some embodiments provide compositions comprising one or more green tea extracts formulated as green tea extract compositions. In certain embodiments, the green tea extract compositions can comprise epigallocatechin gallate (EGCG), epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG), or any combination thereof. In some embodiments, the green tea extract compositions described herein can comprise a pharma- ceutically acceptable vehicle, carrier, or diluent.

[0016] The structure of EGCG is shown below. [ka]

[0017] The structure of EC is shown below. [ka]

[0018] The structure of the EGC is shown below. [ka]

[0019] The structure of an ECG is shown below. [ka]

[0020] In some embodiments, the green tea extract composition described herein may contain at least two of EGCG, EC, EGC, and ECG. For example, the green tea extract composition may contain EGCG and EC present in a ratio of about 1:1, or about 20:1 to about 1:20 of EGCG to EC, or any ratio therebetween. In some embodiments, the green tea extract composition may contain EGCG and EGC present in a ratio of about 1:1, or about 20:1 to about 1:20 of EGCG to EGC, or any ratio therebetween. In certain embodiments, the green tea extract composition may contain EGCG and ECG present in a ratio of about 1:1, or about 20:1 to about 1:20 of EGCG to ECG, or any ratio therebetween. In some embodiments, the green tea extract composition may contain EC and EGC present in a ratio of about 1:1, or about 20:1 to about 1:20 of EC to EGC, or any ratio therebetween. In certain embodiments, the green tea extract composition can include EC and ECG present in a ratio of EC to ECG of about 1:1, or about 20:1 to about 1:20, or any ratio therebetween. In some embodiments, the green tea extract composition can include EGC and ECG present in a ratio of EGC to ECG of about 1:1, or about 20:1 to about 1:20, or any ratio therebetween. Furthermore, any two of the above compounds can be present in a ratio of about 20:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:20, or any ratio therebetween. In light of the results and discussion contained herein, one of ordinary skill in the art would understand how to formulate the green tea extract compositions of the present disclosure to achieve the results described herein.

[0021] In certain embodiments, the green tea extract composition described herein may contain three or more of EGCG, EC, EGC, and ECG. The three or more compounds may be present in a ratio. Ratios may be understood to include "parts" of any compound. For example, a green tea extract composition may contain a 4:1:10 ratio of EGCG, EC, EGC, which corresponds to 4 parts EGCG, 1 part EC, and 10 parts EGC. The individual amounts of any of the above compounds may be as low as 1 part, as high as 20 parts, or any value therebetween. In view of the results and discussion contained herein, one skilled in the art would understand how to formulate the green tea extract composition of the present disclosure to obtain the results described herein.

[0022] Some embodiments provide compositions comprising one or more phycocyanin-related compounds formulated as a phycocyanin composition. As used herein, the term "phycocyanin-related compounds" refers to compounds that are chromoproteins found in Spirulina or obtained therefrom by either extraction, enzymatic degradation or other methods known in the art. Representative examples of phycocyanin-related compounds include, but are not limited to, phycocyanin, phycocyanin extracts, phycocyanin peptides, phycocyanin oligopeptides, and the like. In certain embodiments, the phycocyanin composition may comprise phycocyanin, phycocyanin extracts, phycocyanin peptides, phycocyanin oligopeptides, or any combination thereof. In some embodiments, the phycocyanin compositions described herein may comprise a pharma- ceutically acceptable vehicle, carrier, or diluent.

[0023] In some embodiments, the phycocyanin compositions described herein may comprise at least two of phycocyanin or an extract thereof, phycocyanin peptides, or phycocyanin oligopeptides. For example, the phycocyanin composition may comprise phycocyanin and phycocyanin extract present in a ratio of about 1:1, or about 20:1 to about 1:20 of phycocyanin to phycocyanin extract, or any ratio therebetween. In some embodiments, the phycocyanin composition may comprise phycocyanin and phycocyanin peptides present in a ratio of about 1:1, or about 20:1 to about 1:20 of phycocyanin to phycocyanin peptide, or any ratio therebetween. In certain embodiments, the green tea extract composition may comprise phycocyanin and phycocyanin oligopeptides present in a ratio of about 1:1, or about 20:1 to about 1:20 of phycocyanin to phycocyanin oligopeptide, or any ratio therebetween. In some embodiments, the phycocyanin composition can include phycocyanin extract and phycocyanin peptides present in a ratio of about 1:1, or about 20:1 to about 1:20 of phycocyanin extract to phycocyanin peptide, or any ratio therebetween. In certain embodiments, the green tea extract composition can include phycocyanin extract and phycocyanin oligopeptides present in a ratio of about 1:1, or about 20:1 to about 1:20 of phycocyanin extract to phycocyanin oligopeptide, or any ratio therebetween. In some embodiments, the green tea extract composition can include phycocyanin peptide and phycocyanin oligopeptide present in a ratio of about 1:1, or about 20:1 to about 1:20 of phycocyanin peptide to phycocyanin oligopeptide, or any ratio therebetween. Further, any two of the above compounds can be present in a ratio of about 20:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:20, or any ratio therebetween.Given the results and discussion contained herein, one of skill in the art would understand how to formulate the phycocyanin compositions of the present disclosure to obtain the results described herein.

[0024] In certain embodiments, the phycocyanin compositions described herein may contain three or more of phycocyanin, phycocyanin extract, phycocyanin peptides, and phycocyanin oligopeptides. The three or more compounds may be present in a ratio. Ratios can be understood to include "parts" of any compound. For example, a phycocyanin composition may contain a 4:1:10 ratio of phycocyanin, phycocyanin peptides, and phycocyanin oligopeptides, which corresponds to 4 parts phycocyanin, 1 part phycocyanin peptide, and 10 parts phycocyanin oligopeptide. The individual amounts of any of the above compounds may be as low as 1 part, as high as 20 parts, or any value therebetween. In view of the results and discussion contained herein, one of skill in the art would understand how to formulate the phycocyanin compositions of the present disclosure to obtain the results described herein.

[0025] Some embodiments provide compositions comprising a curcumin composition as described herein, a green tea extract composition as described herein, a phycocyanin composition as described herein, or any combination thereof formulated as a combination composition.

[0026] In some embodiments, the combination composition described herein may comprise at least two of the curcumin composition described herein, the green tea extract composition described herein, and the phycocyanin composition described herein. For example, the combination composition may comprise the curcumin composition described herein and the green tea extract composition described herein, present in a ratio of about 1:1, or about 20:1 to about 1:20 of the curcumin composition described herein to the green tea extract composition described herein, or in any ratio therebetween. In some embodiments, the combination composition may comprise the curcumin composition described herein and the phycocyanin composition described herein, present in a ratio of about 1:1, or about 20:1 to about 1:20 of the curcumin composition described herein to the phycocyanin composition described herein, or in any ratio therebetween. In certain embodiments, the combination composition can include a green tea extract composition as described herein and a phycocyanin composition as described herein, present in a ratio of about 1:1, or about 20:1 to about 1:20 of the green tea extract composition as described herein to the phycocyanin composition as described herein, or in any ratio therebetween. Furthermore, any two of the above compositions comprising the combination composition can be present in a ratio of about 20:1, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, about 2:1, about 1:1, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:20, or in any ratio therebetween. In view of the results and discussion contained herein, one of skill in the art would know how to formulate the combination composition of the present disclosure to obtain the results described herein.

[0027] In certain embodiments, the combination compositions described herein may include a ratio of a curcumin composition described herein, a green tea extract composition described herein, and a phycocyanin composition described herein. The ratio of the curcumin composition, the green tea extract composition, and the phycocyanin is about 1:1:1, 1:1:2, 1:1:3, 1:1:4, 1:1:5, 1:1:6, 1:1:7, 1:1:8, 1:1:9, 1:1:10, 1:2:1, 1:2:2, 1:2:3, 1:2:4, 1:2:5, 1:2:6, 1:2:7, 1:2:8, 1:2:9, 1:2:10, 1:3:1, 1:3:2, 1:3:3, 1:3:4, 1:3:5, 1:3:6, 1:3:7, 1:3:8, 1:3:9, 1:3:10, 1:4:1, 1:4:2, 1: 4:3, 1:4:4, 1:4:5, 1:4:6, 1:4:7, 1:4:8, 1:4:9, 1:4:10, 1:5:1, 1:5:2, 1:5:3, 1:5:4, 1:5:5, 1:5:6, 1:5:7, 1:5:8, 1:5:9, 1:5:10, 1:6:1, 1:6:2, 1:6:3, 1:6:4, 1:6:5, 1:6:6, 1:6:7, 1:6:8, 1:6:9, 1:6:10, 1:7:1, 1:7:2, 1:7:3, 1:7:4, 1:7:5, 1:7:6, 1:7:7, 1:7:8, 1:7:9, 1:7 :10, 1:8:1, 1:8:2, 1:8:3, 1:8:4, 1:8:5, 1:8:6, 1:8:7, 1:8:8, 1:8:9, 1:8:10, 1:9:1, 1:9:2, 1:9:3, 1:9:4, 1:9:5, 1:9:6, 1:9:7, 1:9:8, 1:9:9, 1:9:10, 1:10:1, 1:10:2, 1:10:3, 1:10:4, 1:10:5, 1:10:6, 1:10:7, 1:10:8, 1:10:9, 1:10:10, 2:1:1, 2:1:2, 2:1:3, 2:1:4, 2:1:5 , 2:1:6, 2:1:7, 2:1:8, 2:1:9, 2:1:10, 2:2:1, 2:2:2, 2:2:3, 2:2:4, 2:2:5, 2:2:6, 2:2:7, 2:2:8, 2:2:9, 2:2:10, 2:3:1, 2:3:2, 2:3:3, 2:3:4, 2:3:5, 2:3:6, 2:3:7, 2:3:8, 2:3:9, 2:3:10, 2:4:1, 2:4:2, 2:4:3, 2:4:4, 2:4:5, 2:4:6, 2:4:7, 2:4:8, 2:4:9, 2:4:10, 2:5:1, 2:5:2,2:5:3、2:5:4、2:5:5、2:5:6、2:5:7、2:5:8、2:5:9、2:5:10、2:6:1、2:6:2、2:6:3、2:6:4、2:6:5、2:6:6、2:6:7、2:6:8、2:6:9、2:6:10、2:7:1、2:7:2、2:7:3、2:7:4、2:7:5、2:7:6、2:7:7、2:7:8、2:7:9、2:7:10、2:8:1、2:8:2、2:8:3、2:8:4、2:8:5、2:8:6、2:8:7、2:8:8、2:8:9、2:8:10、2:9:1、2:9:2、2:9:3、2:9:4、2:9:5、2:9:6、2:9:7、2:9:8、2:9:9、2:9:10、2:10:1、2:10:2、2:10:3、2:10:4、2:10:5、2:10:6、2:10:7、2:10:8、2:10:9、2:10:10、3:1:1、3:1:2、3:1:3、3:1:4、3:1:5、3:1:6、3:1:7、3:1:8、3:1:9、3:1:10、3:2:1、3:2:2、3:2:3、3:2:4、3:2:5、3:2:6、3:2:7、3:2:8、3:2:9、3:2:10、3:3:1、3:3:2、3:3:3、3:3:4、3:3:5、3:3:6、3:3:7、3:3:8、3:3:9、3:3:10、3:4:1、3:4:2、3:4:3、3:4:4、3:4:5、3:4:6、3:4:7、3:4:8、3:4:9、3:4:10、3:5:1、3:5:2、3:5:3、3:5:4、3:5:5、3:5:6、3:5:7、3:5:8、3:5:9、3:5:10、3:6:1、3:6:2、3:6:3、3:6:4、3:6:5、3:6:6、3:6:7、3:6:8、3:6:9、3:6:10、3:7:1、3:7:2、3:7:3、3:7:4、3:7:5、3:7:6、3:7:7、3:7:8、3:7:9、3:7:10、3:8:1、3:8:2、3:8:3、3:8:4、3:8:5、3:8:6、3:8:7、3:8:8、3:8:9、3:8:10、3:9:1、3:9:2、3:9:3、3:9:4、3:9:5、3:9:6、3:9:7、3:9:8、3:9:9、3:9:10、3:10:1、3:10:2、3:10:3、3:10:4、3:10:5、3:10:6、3:10:7、3:10:8、3:10:9、3:10:10、4:1:1、4:1:2、4:1:3、4:1:4、4:1:5、4:1:6、4:1:7、4:1:8、4:1:9、4:1:10、4:2:1、4:2:2、4:2:3、4:2:4、4:2:5、4:2:6、4:2:7、4:2:8、4:2:9、4:2:10、4:3:1、4:3:2、4:3:3、4:3:4、4:3:5、4:3:6、4:3:7、4:3:8、4:3:9、4:3:10、4:4:1、4:4:2、4:4:3、4:4:4、4:4:5、4:4:6、4:4:7、4:4:8、4:4:9、4:4:10、4:5:1、4:5:2、4:5:3、4:5:4、4:5:5、4:5:6、4:5:7、4:5:8、4:5:9、4:5:10、4:6:1、4:6:2、4:6:3、4:6:4、4:6:5、4:6:6、4:6:7、4:6:8、4:6:9、4:6:10、4:7:1、4:7:2、4:7:3、4:7:4、4:7:5、4:7:6、4:7:7、4:7:8、4:7:9、4:7:10、4:8:1、4:8:2、4:8:3、4:8:4、4:8:5、4:8:6、4:8:7、4:8:8、4:8:9、4:8:10、4:9:1、4:9:2、4:9:3、4:9:4、4:9:5、4:9:6、4:9:7、4:9:8、4:9:9、4:9:10、4:10:1、4:10:2、4:10:3、4:10:4、4:10:5、4:10:6、4:10:7、4:10:8、4:10:9、4:10:10、5:1:1、5:1:2、5:1:3、5:1:4、5:1:5、5:1:6、5:1:7、5:1:8、5:1:9、5:1:10、5:2:1、5:2:2、5:2:3、5:2:4、5:2:5、5:2:6、5:2:7、5:2:8、5:2:9、5:2:10、5:3:1、5:3:2、5:3:3、5:3:4、5:3:5、5:3:6、5:3:7、5:3:8、5:3:9、5:3:10、5:4:1、5:4:2、5:4:3、5:4:4、5:4:5、5:4:6、5:4:7、5:4:8、5:4:9、5:4:10、5:5:1、5:5:2、5:5:3、5:5:4、5:5:5、5:5:6、5:5:7、5:5:8、5:5:9、5:5:10、5:6:1、5:6:2、5:6:3、5:6:4、5:6:5、5:6:6、5:6:7、5:6:8、5:6:9、5:6:10、5:7:1、5:7:2、5:7:3、5:7:4、5:7:5、5:7:6、5:7:7、5:7:8、5:7:9、5:7:10、5:8:1、5:8:2、5:8:3、5:8:4、5:8:5、5:8:6、5:8:7、5:8:8、5:8:9、5:8:10、5:9:1、5:9:2、5:9:3、5:9:4、5:9:5、5:9:6、5:9:7、5:9:8、5:9:9、5:9:10、5:10:1、5:10:2、5:10:3、5:10:4、5:10:5、5:10:6、5:10:7、5:10:8、5:10:9、5:10:10、6:1:1、6:1:2、6:1:3、6:1:4、6:1:5、6:1:6、6:1:7、6:1:8、6:1:9、6:1:10、6:2:1、6:2:2、6:2:3、6:2:4、6:2:5、6:2:6、6:2:7、6:2:8、6:2:9、6:2:10、6:3:1、6:3:2、6:3:3、6:3:4、6:3:5、6:3:6、6:3:7、6:3:8、6:3:9、6:3:10、6:4:1、6:4:2、6:4:3、6:4:4、6:4:5、6:4:6、6:4:7、6:4:8、6:4:9、6:4:10、6:5:1、6:5:2、6:5:3、6:5:4、6:5:5、6:5:6、6:5:7、6:5:8、6:5:9、6:5:10、6:6:1、6:6:2、6:6:3、6:6:4、6:6:5、6:6:6、6:6:7、6:6:8、6:6:9、6:6:10、6:7:1、6:7:2、6:7:3、6:7:4、6:7:5、6:7:6、6:7:7、6:7:8、6:7:9、6:7:10、6:8:1、6:8:2、6:8:3、6:8:4、6:8:5、6:8:6、6:8:7、6:8:8、6:8:9、6:8:10、6:9:1、6:9:2、6:9:3、6:9:4、6:9:5、6:9:6、6:9:7、6:9:8、6:9:9、6:9:10、6:10:1、6:10:2、6:10:3、6:10:4、6:10:5、6:10:6、6:10:7、6:10:8、6:10:9、6:10:10、7:1:1、7:1:2、7:1:3、7:1:4、7:1:5、7:1:6、7:1:7、7:1:8、7:1:9、7:1:10、7:2:1、7:2:2、7:2:3、7:2:4、7:2:5、7:2:6、7:2:7、7:2:8、7:2:9、7:2:10、7:3:1、7:3:2、7:3:3、7:3:4、7:3:5、7:3:6、7:3:7、7:3:8、7:3:9、7:3:10、7:4:1、7:4:2、7:4:3、7:4:4、7:4:5、7:4:6、7:4:7、7:4:8、7:4:9、7:4:10、7:5:1、7:5:2、7:5:3、7:5:4、7:5:5、7:5:6、7:5:7、7:5:8、7:5:9、7:5:10、7:6:1、7:6:2、7:6:3、7:6:4、7:6:5、7:6:6、7:6:7、7:6:8、7:6:9、7:6:10、7:7:1、7:7:2、7:7:3、7:7:4、7:7:5、7:7:6、7:7:7、7:7:8、7:7:9、7:7:10、7:8:1、7:8:2、7:8:3、7:8:4、7:8:5、7:8:6、7:8:7、7:8:8、7:8:9、7:8:10、7:9:1、7:9:2、7:9:3、7:9:4、7:9:5、7:9:6、7:9:7、7:9:8、7:9:9、7:9:10、7:10:1、7:10:2、7:10:3、7:10:4、7:10:5、7:10:6、7:10:7、7:10:8、7:10:9、7:10:10、8:1:1、8:1:2、8:1:3、8:1:4、8:1:5、8:1:6、8:1:7、8:1:8、8:1:9、8:1:10、8:2:1、8:2:2、8:2:3、8:2:4、8:2:5、8:2:6、8:2:7、8:2:8、8:2:9、8:2:10、8:3:1、8:3:2、8:3:3、8:3:4、8:3:5、8:3:6、8:3:7、8:3:8、8:3:9、8:3:10、8:4:1、8:4:2、8:4:3、8:4:4、8:4:5、8:4:6、8:4:7、8:4:8、8:4:9、8:4:10、8:5:1、8:5:2、8:5:3、8:5:4、8:5:5、8:5:6、8:5:7、8:5:8、8:5:9、8:5:10、8:6:1、8:6:2、8:6:3、8:6:4、8:6:5、8:6:6、8:6:7、8:6:8、8:6:9、8:6:10、8:7:1、8:7:2、8:7:3、8:7:4、8:7:5、8:7:6、8:7:7、8:7:8、8:7:9、8:7:10、8:8:1、8:8:2、8:8:3、8:8:4、8:8:5、8:8:6、8:8:7、8:8:8、8:8:9、8:8:10、8:9:1、8:9:2、8:9:3、8:9:4、8:9:5、8:9:6、8:9:7、8:9:8、8:9:9、8:9:10、8:10:1、8:10:2、8:10:3、8:10:4、8:10:5、8:10:6、8:10:7、8:10:8、8:10:9、8:10:10、9:1:1、9:1:2、9:1:3、9:1:4、9:1:5、9:1:6、9:、 1:7、9:1:8、9:1:9、9:1:10、9:2:1、9:2:2、9:2:3、9:2:4、9:2:5、9:2:6、9:2:7、9:2:8、9:2:9、9:2:10、9:3:1、9:3:2、9:3:3、9:3:4、9:3:5、9:3:6、9:3:7、9:3:8、9:3:9、9:3:10、9:4:1、9:4:2、9:4:3、9:4:4、9:4:5、9:4:6、9:4:7、9:4:8、9:4:9、9:4:10、9:5:1、9:5:2、9:5:3、9:5:4、9:5:5、9:5:6、9:5:7、9:5:8、9:5:9、9:5:10、9:6:1、9:6:2、9:6:3、9:6:4、9:6:5、9:6:6、9:6:7、9:6:8、9:6:9、9:6:10、9:7:1、9:7:2、9:7:3、9:7:4、9:7:5、9:7:6、9:7:7、9:7:8、9:7:9、9:7:10、9:8:1、9:8:2、9:8:3、9:8:4、9:8:5、9:8:6、9:8:7、9:8:8、9:8:9、9:8:10、9:9:1、9:9:2、9:9:3、9:9:4、9:9:5、9:9:6、9:9:7、9:9:8、9:9:9、9:9:10、9:10:1、9:10:2、9:10:3、9:10:4、9:10:5、9:10:6、9:10:7、9:10:8、9:10:9、9:10:10、10:1:1、10:1:2、10:1:3、10:1:4、10:1:5、10:1:6、10:1:7、10:1:8、10:1:9、10:1:10、10:2:1、10:2:2、10:2:3、10:2:4、10:2:5、10:2:6、10:2:7、10:2:8、10:2:9、10:2:10、10:3:1、10:3:2、10:3:3、10:3:4、10:3:5、10:3:6、10:3:7、10:3:8、10:3:9、10:3:10、10:4:1、10:4:2、10:4:3、10:4:4、10:4:5、10:4:6、10:4:7、10:4:8、10:4:9、10:4:10、10:5:1、10:5:2、10:5:3、10:5:4、10:5:5、10:5:6、10:5:7、10:5:8、10:5:9、10:5:10、10:6:1、10:6:2、10:6:3、10:6:4、10:6:5、10:6:6、10:6:7、10:6:8、10:6:9、10:6:10, 10:7:1, 10:7:2, 10:7:3, 10:7:4, 10:7:5, 10:7:6, 10:7:7, 10:7:8, 10:7:9, 10:7:10, 10:8:1, 10:8:2, 10:8:3, 10:8:4, 10:8:5, 10:8:6, 10:8:7, 10:8:8, 10:8:9, 10:8:10, 10:9:1, 10:9 10:9:1, 10:10:2, 10:9:3, 10:9:4, 10:9:5, 10:9:6, 10:9:7, 10:9:8, 10:9:9, 10:9:10, 10:10:1, 10:10:2, 10:10:3, 10:10:4, 10:10:5, 10:10:6, 10:10:7, 10:10:8, 10:10:9, 10:10:10, or any ratio therebetween. In view of the results and discussion contained herein, one skilled in the art would know how to formulate a combination composition comprising a curcumin composition as described herein, a green tea extract as described herein, and a phycocyanin composition as described herein to achieve the results described herein.

[0028] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 diferuloylmethane, EGCG, phycocyanin or an extract thereof, about 6:3:1 diferuloylmethane, EGCG, phycocyanin or an extract thereof, about 7.2:1.8:1 diferuloylmethane, EGCG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 diferuloylmethane, EGCG, phycocyanin or an extract thereof.

[0029] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 diferuloylmethane, EC, phycocyanin or an extract thereof, about 6:3:1 diferuloylmethane, EC, phycocyanin or an extract thereof, about 7.2:1.8:1 diferuloylmethane, EC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 diferuloylmethane, EC, phycocyanin or an extract thereof.

[0030] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 diferuloylmethane, EGC, phycocyanin or an extract thereof, about 6:3:1 diferuloylmethane, EGC, phycocyanin or an extract thereof, about 7.2:1.8:1 diferuloylmethane, EGC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 diferuloylmethane, EGC, phycocyanin or an extract thereof.

[0031] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 diferuloylmethane, ECG, phycocyanin or an extract thereof, about 6:3:1 diferuloylmethane, ECG, phycocyanin or an extract thereof, about 7.2:1.8:1 diferuloylmethane, ECG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 diferuloylmethane, ECG, phycocyanin or an extract thereof.

[0032] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 DMC, EGCG, phycocyanin or an extract thereof, about 6:3:1 DMC, EGCG, phycocyanin or an extract thereof, about 7.2:1.8:1 DMC, EGCG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 DMC, EGCG, phycocyanin or an extract thereof.

[0033] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 DMC, EC, phycocyanin or an extract thereof, about 6:3:1 DMC, EC, phycocyanin or an extract thereof, about 7.2:1.8:1 DMC, EC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 DMC, EC, phycocyanin or an extract thereof.

[0034] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 DMC, EGC, phycocyanin or an extract thereof, about 6:3:1 DMC, EGC, phycocyanin or an extract thereof, about 7.2:1.8:1 DMC, EGC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 DMC, EGC, phycocyanin or an extract thereof.

[0035] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 DMC, ECG, phycocyanin or an extract thereof, about 6:3:1 DMC, ECG, phycocyanin or an extract thereof, about 7.2:1.8:1 DMC, ECG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 DMC, ECG, phycocyanin or an extract thereof.

[0036] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 BDMC, EGCG, phycocyanin or an extract thereof, about 6:3:1 BDMC, EGCG, phycocyanin or an extract thereof, about 7.2:1.8:1 BDMC, EGCG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 BDMC, EGCG, phycocyanin or an extract thereof.

[0037] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 BDMC, EC, phycocyanin or an extract thereof, about 6:3:1 BDMC, EC, phycocyanin or an extract thereof, about 7.2:1.8:1 BDMC, EC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 BDMC, EC, phycocyanin or an extract thereof.

[0038] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 BDMC, EGC, phycocyanin or an extract thereof, about 6:3:1 BDMC, EGC, phycocyanin or an extract thereof, about 7.2:1.8:1 BDMC, EGC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 BDMC, EGC, phycocyanin or an extract thereof.

[0039] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 BDMC, ECG, phycocyanin or an extract thereof, about 6:3:1 BDMC, ECG, phycocyanin or an extract thereof, about 7.2:1.8:1 BDMC, ECG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 BDMC, ECG, phycocyanin or an extract thereof.

[0040] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 tetrahydrocurcumin, EGCG, phycocyanin or an extract thereof, about 6:3:1 tetrahydrocurcumin, EGCG, phycocyanin or an extract thereof, about 7.2:1.8:1 tetrahydrocurcumin, EGCG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 tetrahydrocurcumin, EGCG, phycocyanin or an extract thereof.

[0041] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 tetrahydrocurcumin, EC, phycocyanin or an extract thereof, about 6:3:1 tetrahydrocurcumin, EC, phycocyanin or an extract thereof, about 7.2:1.8:1 tetrahydrocurcumin, EC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 tetrahydrocurcumin, EC, phycocyanin or an extract thereof.

[0042] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 tetrahydrocurcumin, EGC, phycocyanin or an extract thereof, about 6:3:1 tetrahydrocurcumin, EGC, phycocyanin or an extract thereof, about 7.2:1.8:1 tetrahydrocurcumin, EGC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 tetrahydrocurcumin, EGC, phycocyanin or an extract thereof.

[0043] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 tetrahydrocurcumin, ECG, phycocyanin or extract thereof, about 6:3:1 tetrahydrocurcumin, ECG, phycocyanin or extract thereof, about 7.2:1.8:1 tetrahydrocurcumin, ECG, phycocyanin or extract thereof, or about 8:1:1 to about 1:8:1 tetrahydrocurcumin, ECG, phycocyanin or extract thereof.

[0044] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 dihydrocurcumin, EGCG, phycocyanin or an extract thereof, about 6:3:1 dihydrocurcumin, EGCG, phycocyanin or an extract thereof, about 7.2:1.8:1 dihydrocurcumin, EGCG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 dihydrocurcumin, EGCG, phycocyanin or an extract thereof.

[0045] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 dihydrocurcumin, EC, phycocyanin or an extract thereof, about 6:3:1 dihydrocurcumin, EC, phycocyanin or an extract thereof, about 7.2:1.8:1 dihydrocurcumin, EC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 dihydrocurcumin, EC, phycocyanin or an extract thereof.

[0046] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 dihydrocurcumin, EGC, phycocyanin or an extract thereof, about 6:3:1 dihydrocurcumin, EGC, phycocyanin or an extract thereof, about 7.2:1.8:1 dihydrocurcumin, EGC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 dihydrocurcumin, EGC, phycocyanin or an extract thereof.

[0047] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 dihydrocurcumin, ECG, phycocyanin or an extract thereof, about 6:3:1 dihydrocurcumin, ECG, phycocyanin or an extract thereof, about 7.2:1.8:1 dihydrocurcumin, ECG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 dihydrocurcumin, ECG, phycocyanin or an extract thereof.

[0048] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 hexahydrocurcumin, EGCG, phycocyanin or an extract thereof, about 6:3:1 hexahydrocurcumin, EGCG, phycocyanin or an extract thereof, about 7.2:1.8:1 hexahydrocurcumin, EGCG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 hexahydrocurcumin, EGCG, phycocyanin or an extract thereof.

[0049] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 hexahydrocurcumin, EC, phycocyanin or an extract thereof, about 6:3:1 hexahydrocurcumin, EC, phycocyanin or an extract thereof, about 7.2:1.8:1 hexahydrocurcumin, EC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 hexahydrocurcumin, EC, phycocyanin or an extract thereof.

[0050] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 hexahydrocurcumin, EGC, phycocyanin or an extract thereof, about 6:3:1 hexahydrocurcumin, EGC, phycocyanin or an extract thereof, about 7.2:1.8:1 hexahydrocurcumin, EGC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 hexahydrocurcumin, EGC, phycocyanin or an extract thereof.

[0051] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 hexahydrocurcumin, ECG, phycocyanin or an extract thereof, about 6:3:1 hexahydrocurcumin, ECG, phycocyanin or an extract thereof, about 7.2:1.8:1 hexahydrocurcumin, ECG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 hexahydrocurcumin, ECG, phycocyanin or an extract thereof.

[0052] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 octahydrocurcumin, EGCG, phycocyanin or an extract thereof, about 6:3:1 octahydrocurcumin, EGCG, phycocyanin or an extract thereof, about 7.2:1.8:1 octahydrocurcumin, EGCG, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 octahydrocurcumin, EGCG, phycocyanin or an extract thereof.

[0053] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 octahydrocurcumin, EC, phycocyanin or an extract thereof, about 6:3:1 octahydrocurcumin, EC, phycocyanin or an extract thereof, about 7.2:1.8:1 octahydrocurcumin, EC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 octahydrocurcumin, EC, phycocyanin or an extract thereof.

[0054] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 octahydrocurcumin, EGC, phycocyanin or an extract thereof, about 6:3:1 octahydrocurcumin, EGC, phycocyanin or an extract thereof, about 7.2:1.8:1 octahydrocurcumin, EGC, phycocyanin or an extract thereof, or about 8:1:1 to about 1:8:1 octahydrocurcumin, EGC, phycocyanin or an extract thereof.

[0055] In certain embodiments, the combination composition may comprise about 4.5:4.5:1 octahydrocurcumin, ECG, phycocyanin or extract thereof, about 6:3:1 octahydrocurcumin, ECG, phycocyanin or extract thereof, about 7.2:1.8:1 octahydrocurcumin, ECG, phycocyanin or extract thereof, or about 8:1:1 to about 1:8:1 octahydrocurcumin, ECG, phycocyanin or extract thereof.

[0056] In some embodiments, the combination compositions described herein may contain from about 10 μg to about 10 g of one or more of the curcumin compositions described herein, the green tea extract compositions described herein, and the phycocyanin compositions described herein. For example, some embodiments may contain from about 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 125 μg, 150 μg, 175 μg, 200 μg, 225 μg, 250 μg, 275 μg, 300 μg, 325 μg, 350 μg, 375 μg, 400 μg, 425 μg, 450 μg, 475 μg, 480 μg, 490 μg, 500 μg, 510 μg, 520 μg, 530 μg, 540 μg, 550 μg, 560 μg, 570 μg, 580 μg, 590 μg, 60 ... μg, 500μg, 525μg, 575μg, 600μg, 625μg, 650μg, 675μg, 700μg, 725μg, 750μg, 775μg, 800μg, 825μg, 850μg, 875μg, 900μg , 925μg, 950μg, 975μg, 1000μg, 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 55mg, 60mg, 65mg, 70mg, 75mg , 80mg, 85mg, 90mg, 95mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, 300mg, 325mg, 350mg, 375mg, 400mg , 425mg, 450mg, 475mg, 500mg, 525mg, 550mg, 575mg, 600mg, 625mg, 650mg, 675mg, 700mg, 725mg, 750mg, 775mg, 800mg, 82 Combination compositions comprising one or more of the curcumin compositions described herein, the green tea extract compositions described herein, and the phycocyanin compositions described herein, present in an amount of 5 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, 1000 mg, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, or any two of the ranges or amounts set forth above, or any other range or amount disclosed herein.

[0057] In some embodiments, the curcumin composition, green tea extract composition, phycocyanin composition or combination composition described herein may include one or more supplementary ingredients. As used herein, the term supplementary ingredients may refer to essential fatty acids such as linolenic acid and linoleic acid, and essential amino acids such as tryptophan, lysine, methionine, phenylalanine, threonine, valine, leucine, isoleucine, arginine and histidine, and n-acetylcysteine. Vitamins such as retinol (vitamin A), thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), pantothenic acid (vitamin B5), pyridoxine, pyridoxamine or pyridoxal (vitamin B6), biotin (vitamin B7) or a pharma- ceutically acceptable salt thereof, folic acid (vitamin B9) or a pharma- ceutically acceptable salt thereof, cobalamin (vitamin B12), choline, ascorbic acid (vitamin C) or a pharma- ceutically acceptable salt thereof, ergocalciferol (vitamin D2), calciferol (vitamin D3), 22-dihydroergocalciferol (vitamin D4), cytocalciferol (vitamin D5), tocopherol (vitamin E), phylloquinone (vitamin K1), menaquinone (vitamin K2), menadione (vitamin K3), or combinations thereof, may also be included in the supplemental ingredients. Other vitamins not explicitly mentioned would be readily predicted by one of ordinary skill in the art in view of the disclosure contained herein. The supplemental ingredients can further include dietary minerals such as, for example, chromium, bromine, cobalt, copper, fluorine, germanium, iodine, iron, magnesium, manganese, molybdenum, potassium, selenium, silicon, zinc, calcium, phosphorus, sodium, sulfur, and vanadium.Supplementary ingredients can also include cranberry extract, turmeric, royal jelly, acai berry, beet root, coral calcium, oyster shell, gotu kola, gingko biloba, lions mane mushroom, pomegranate, hibiscus flower, strawberry powder, dandelion root, celery powder, parsley powder, peppermint leaf, cinnamon powder, maca root, nicotinamide riboside, resveratrol, NAD+ precursors, coenzyme Q10, omega-3-fatty acids, cabbage powder, pterostilbene, nicotinamide mononucleotide, and combinations thereof. Supplementary ingredients can include nitrates, such as citrulline nitrate, creatine nitrate, and beta-alanine nitrate. The compositions described herein can include one or more of the supplementary ingredients listed above, as will be appreciated by those skilled in the art.

[0058] In some embodiments, the amount of at least one supplemental ingredient disclosed herein can be from about 10 μg to about 10 g. For example, the amount of at least one supplemental ingredient in the composition can be from about 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 125 μg, 150 μg, 175 μg, 200 μg, 225 μg, 250 μg, 275 μg, 30 ... 0μg, 325μg, 350μg, 375μg, 400μg, 425μg, 450μg, 475μg, 500μg, 525μg, 575μg, 600μg, 625μg, 650μg, 675μg, 700μg, 725μg, 750μg, 775μg, 800μg, 825μg, 850μg, 875μg, 900μg, 925μg, 950μg, 975μg, 1000μg g, 5mg, 10mg, 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, 300mg, 32 5mg, 350mg, 375mg, 400mg, 425mg, 450mg, 475mg, 500mg, 525mg, 550mg, 575mg, 600mg, 625mg, 650mg, 6 The amount can be 75 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 825 mg, 850 mg, 875 mg, 900 mg, 925 mg, 950 mg, 975 mg, 1000 mg, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, 10 g, or a range or amount between any two of the above values ​​or any other range or amount disclosed herein.

[0059] In certain embodiments, the curcumin compositions, green tea extract compositions, phycocyanin compositions, or combination compositions described herein can be formulated as a dietary supplement or a pharmaceutical.

[0060] The compounds described herein, including the curcumin composition, green tea extract composition, and phycocyanin composition, may be active agents present in a therapeutically effective amount. By way of example, the "therapeutically effective amount" and / or "effective amount" of the compounds disclosed herein (on a weight administered basis per subject weight basis) may be, for example, 0.1 μg / kg, 0.5 μg / kg, 1 μg / kg, 1.5 μg / kg, 2.0 μg / kg, 2.5 μg / kg, 3.0 μg / kg, 3.5 μg / kg, 4.0 μg / kg, 4.5 μg / kg, 5.0 μg / kg, 10 μg / kg, 15 μg / kg, 20 μg / kg, 25 μg / kg, 30 μg / kg, 35 μg / kg, 40 μg / kg, 45 μg / kg, 50 μg / kg, 60 μg / kg, 70 μg / kg, 75 μg / kg, 80 μg / kg, 85 μg / kg, 90 μg / kg, 95 μg / kg, 10 ... g / kg, 50μg / kg, 55μg / kg, 60μg / kg, 65μg / kg, 70μg / kg, 75μg / kg, 80μg / kg, 85μg / kg, 90μg / kg, 95μg / kg, 100μg / kg, 150μg / kg, 200μg / kg kg, 250μg / kg, 300μg / kg, 350μg / kg, 400μg / kg, 450μg / kg, 500μg / kg, 550μg / kg, 600μg / kg, 650μg / kg, 700μg / kg, 750μg / kg, 80μg / kg 0, 850μg / kg, 900μg / kg, 1mg / kg, 1.5mg.kg, 2.0mg / kg, 2.5mg / kg, 3mg / kg, 3.5mg / kg, 4.0mg / kg, 4.5mg / kg , 5mg / kg, 5.5mg / kg, 6mg / kg, 6.5mg / kg, 7mg / kg, 7.5mg / kg, 8mg / kg, 8.5mg / kg, 9mg / kg, 9.5mg / kg, 10mg / kg The compound can be 10.5 mg / kg, 11 mg / kg, 11.5 mg / kg, 12 mg / kg, 12.5 mg / kg, 13 mg / kg, 13.5 mg / kg, 14 mg / kg, 14.5 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 20 mg / kg, 21 mg / kg, 22 mg / kg, 23 mg / kg, 24 mg / kg, 25 mg / kg, 30 mg / kg, 35 mg / kg, 40 mg / kg, 45 mg / kg, 50 mg / kg, 55 mg / kg, 60 mg / kg, 65 mg / kg, 70 mg / kg or more, or any fraction or integer between any two of the aforementioned amounts.An effective amount can include any of the ranges and amounts discussed herein.

[0061] Thus, in some embodiments, the dosage of the compound in the compositions disclosed herein (corresponding to a therapeutically effective amount) can be preferably from about 10 μg to about 10 g per day. For example, the amount of the composition can be 10 μg, 15 μg, 20 μg, 25 μg, 30 μg, 35 μg, 40 μg, 45 μg, 50 μg, 55 μg, 60 μg, 65 μg, 70 μg, 75 μg, 80 μg, 85 μg, 90 μg, 95 μg, 100 μg, 125 μg, 150 μg, 175 μg, 200 μg, 225 μg, 250 μg, 275 μg, 280 μg, 290 μg, 300 μg, 310 μg, 320 μg, 330 μg, 340 μg, 350 μg, 360 μg, 370 μg, 380 μg, 390 μg, 400 μg, 410 μg, 420 μg, 430 μg, 440 μg, 450 μg, 460 μg, 470 μg, 480 μg, 490 μg, 500 μg, 510 μg, 520 μg, 530 μg, 540 μg, 550 μg, 560 μg, 570 μg, 580 μg, 590 μg, 60 ... μg, 300μg, 325μg, 350μg, 375μg, 400μg, 425μg, 450μg, 475μg, 500μg, 525μg, 575μg, 600μg g, 625μg, 650μg, 675μg, 700μg, 725μg, 750μg, 775μg, 800μg, 825μg, 850μg, 875μg, 900μg , 925μg, 950μg, 975μg, 1000μg, 1.25g, 1.5g, 1.75g, 2.0g, 2.25g, 2.5g, 2.75g, 3.0g, 3.2 5g, 3.5g, 3.5g, 3.75g, 4.0g, 4.25g, 4.5g, 4.75g, 5.0g, 5.25g, 5.5g, 5.75g, 6.0g, 6.25g , 6.5g, 6.75g, 7.0g, 7.25g, 7.5g, 7.75g, 8.0g, 8.25g, 8.5g, 8.75g, 9.0g, 8.25g, 9.5g, 9.75g, 10g, or more, or a range or amount between any two of the abovementioned values ​​or any other range or amount disclosed herein.

[0062] In some embodiments, the curcumin composition described herein, the green tea extract composition described herein, and the phycocyanin composition described herein are provided in a synergistic ratio in a combination composition, and in some cases, the combination composition may be provided as a dietary supplement or a pharmaceutical. The synergistic ratio is not particularly limited. In some embodiments, the synergistic ratio may include 4.5:4.5:1 of the curcumin composition, green tea extract composition, and phycocyanin composition. In some embodiments, the synergistic ratio may include 6:3:1 of the curcumin composition, green tea extract composition, and phycocyanin composition. In some embodiments, the synergistic ratio may include 7.2:1.8:1 of the curcumin composition, green tea extract composition, and phycocyanin composition. In some embodiments, the synergistic ratio may include about 8:1:1 to about 1:8:1 of the curcumin composition, green tea extract composition, and phycocyanin composition.

[0063] In some aspects, the compositions described herein can be administered in the manner described herein on an hourly basis, for example, every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 hours, or any time in between, or daily, every 2, 3, 4, 5, 6, 7, 8, 9, 10 days, biweekly, monthly, or more or less frequently as needed to achieve the desired therapeutic effect.

[0064] In some embodiments, a graded dosing protocol can be utilized in which the subject is administered increasing amounts of the compositions described herein over time. For example, the subject can be administered 100 mg of the compositions described herein per day for 7 days, followed by 200 mg for the next 7 days, followed by 300 mg for the next 7 days. The dosing protocol can also follow a pattern in which the dosage decreases over time. For example, the subject can be administered 300 mg of the compositions described herein per day for 7 days, followed by 200 mg for the next 7 days, followed by 100 mg for the next 7 days. In some embodiments, the methods described herein can be utilized in combination with a calorie restriction protocol in the subject. In certain embodiments, the compositions described herein can be administered before, after, or during a meal. Furthermore, the appropriate dosage of the composition can depend, for example, on the condition being treated, whether the composition is administered for prophylactic or therapeutic purposes, the severity and progression of the condition, previous treatments, the patient's medical history and response to the composition, the type of composition used, and the discretion of the attending physician. The compositions may be suitably administered to the patient at one time or over a series of treatments and may be administered to the patient any time after diagnosis. The compositions may be administered as the sole treatment or in combination with other drugs or treatments that are beneficial in treating the condition in question.

[0065] The present disclosure discloses a combination composition comprising one or more of a curcumin composition, a green tea extract composition and a phycocyanin composition, optionally formulated as a dietary supplement or pharmaceutical, useful as an NK3 antagonist, and methods of using the same. Some embodiments provide a solid dosage form of the composition disclosed herein. Certain embodiments provide an aqueous solution of the composition disclosed herein. The embodiments described herein that include the composition disclosed herein as a dietary supplement mean that the composition disclosed herein is present in a non-natural form, i.e., is provided in a dietary supplement (e.g., in a pill or powder) that is different from that which occurs in nature, or that the dietary supplement provides a non-natural supplement that is not obtained from unsupplemented foods. Some embodiments may further include a matrix material, such as a fatty acid, a fatty acid ester, a triglyceride, an oil, or a lipid solvent. In some embodiments, the composition is a solid composition. In some embodiments, the composition includes a sustained release matrix. In some embodiments, the composition is enteric coated.

[0066] Some embodiments provide physiologically compatible compositions disclosed herein, including hydrates, crystalline forms, polymorphic forms, solid forms having particular bulk or tapped densities, and solid forms having particular particle sizes. Some embodiments provide compositions coated with pharma- ceutically acceptable materials intended to improve their release and / or bioavailability, including, but not limited to, Eudragit®, microcrystalline cellulose, hydroxypropyl methylcellulose phthalate, and the like.

[0067] For oral administration, the compositions disclosed herein can be provided as tablets, aqueous or oily suspensions, powders or granules, emulsions, hard or soft capsules, syrups, elixirs, or beverages. Solid dosage forms such as tablets and capsules may contain enteric coatings. Compositions intended for oral use can be prepared according to any method known in the art for the manufacture of pharma-ceutically acceptable compositions, and such compositions may contain one or more of the following substances: sweeteners, flavoring agents, coloring agents, coatings, and preservatives. Sweeteners and flavoring agents improve the palatability of the preparation. Tablets containing the complex in a mixture with non-toxic pharma-ceutically acceptable excipients suitable for the manufacture of tablets are acceptable. Pharmaceutically acceptable vehicles such as excipients are compatible with the other ingredients of the formulation (and are harmless to the patient). Such excipients include inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents such as corn starch or alginic acid; binding agents such as starch, gelatin or acacia; and lubricants such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be used.

[0068] Formulations for oral use can also be provided as hard gelatin-containing or non-gelatin capsules in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin, or soft gelatin capsules in which the active ingredient is mixed with water or an oil medium such as peanut oil, liquid paraffin or olive oil. Aqueous suspensions can contain the complexes described herein in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include suspending agents, dispersing or wetting agents, one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0069] Oily suspensions can be formulated by suspending the active ingredient in vegetable oils such as arachis oil, olive oil, sesame oil or coconut oil, or mineral oils such as liquid paraffin. Oily suspensions can contain thickening agents such as beeswax, hard paraffin or cetyl alcohol. Sweetening and flavoring agents such as those mentioned above can be added to provide a palatable oral preparation. These compositions can be preserved by the addition of an antioxidant such as ascorbic acid. Powders and granules suitable for preparation of an aqueous suspension by the addition of water can provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Additional excipients, such as sweetening agents, flavoring agents and coloring agents, can also be present.

[0070] Syrups and elixirs can be formulated with sweetening agents, such as glycerol, sorbitol or sucrose, and such preparations may also contain a demulcent, a preservative, a flavouring or a colouring agent.

[0071] Compositions for parenteral administration can be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to methods well known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Suitable diluents include, for example, water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils can conventionally be used as a solvent or suspending medium. For this purpose, any bland fixed oil can be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid can be used in the preparation of injectable preparations as well.

[0072] It will be appreciated that a certain amount of the compounds may be combined with the carrier materials to produce a single dosage form, which will vary depending upon the host treated and the particular mode of administration.

[0073] In some aspects, the compositions described herein may be administered in dietary supplements or formulations designed for animals. In some animal applications, the compounds or compositions may be added to and / or comprised in pet treats or biscuits, such as dog biscuits or cat treats.

[0074] Aqueous suspensions may contain the compounds disclosed herein in admixture with excipients suitable for the manufacture of aqueous suspensions, such as suspending agents, dispersing or wetting agents, one or more preservatives, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0075] The use of controlled release vehicles is readily anticipated by one skilled in the art of pharmacy in light of the disclosure contained herein, and these aspects are applicable to dietary supplements. Technology and products in this field are variably referred to as controlled release, sustained release, sustained action, depot, repository, delayed action, delayed release, and timed release; as used herein, the term "controlled release" is intended to encompass each of the aforementioned technologies.

[0076] A number of controlled release vehicles can be used, including biodegradable or bioerodible polymers such as polylactic acid, polyglycolic acid, and regenerated collagen. Controlled release drug delivery devices can include creams, lotions, tablets, capsules, gels, microspheres, liposomes, ocular inserts, mini-pumps, and other injection devices such as pumps and syringes. Implantable or injectable polymer matrices and transdermal formulations that slowly release the active ingredient can be used in the disclosed methods.

[0077] Controlled release preparations can be obtained through the use of polymers that complex with or absorb the curcumin compositions. Controlled delivery can be effected by choosing appropriate macromolecules such as polyesters, polyamino acids, polyvinylpyrrolidones, ethylene vinyl acetate, methylcellulose, carboxymethylcellulose and protamine sulfate, the concentrations of these macromolecules and the method of incorporation are selected to control the release of the active complex.

[0078] Controlled release of an active complex may be understood to mean any extended release dosage form. The following terms may be considered substantially equivalent to controlled release for the purposes of this disclosure: continuous release, controlled release, delayed release, depot, staged release, extended release, programmed release, prolonged release, scheduled release, proportional release, protracted release, repository, delayed, slow release, spaced release, sustained release, sustained coat, time release, delayed action, extended action, layered sustained action, long acting, prolonged action, sustained action drug and extended release, release in relation to the pH level of the digestive tract and intestine, degradation of molecules based on absorption and bioavailability.

[0079] Hydrogels in which the compositions disclosed herein dissolve in an aqueous medium and release slowly over time can be prepared by copolymerization of hydrophilic monoolefin monomers such as ethylene glycol methacrylate. A matrix device can be used in which the curcumin composition is dispersed in a matrix of a carrier material. The carrier can be porous or non-porous, solid or semi-solid, permeable or impermeable. Alternatively, a device containing a central reservoir of the compositions disclosed herein surrounded by a rate-controlling membrane can be used to control the release of the complex. The rate-controlling membrane includes ethylene-vinyl acetate copolymer or butylene terephthalate / polytetramethylene ether terephthalate. The use of silicone rubber or ethylene-vinyl alcohol depots is also contemplated.

[0080] Controlled release oral formulations can also be used. In some embodiments, the compositions described herein are incorporated into a soluble or erodible matrix, such as a pill or lozenge. In another example, the oral formulation can be a liquid for sublingual administration. These liquid compositions can also be in the form of a gel or paste. Hydrophilic gums, such as hydroxymethylcellulose, are commonly used. Lubricants, such as magnesium stearate, stearic acid, or calcium stearate, can be used to aid in the tableting process.

[0081] In some embodiments, dosing for oral administration may be by a regimen requiring a single administration per day, a single administration every other day, a single administration within 72 hours of the first administration, or multiple spaced administrations throughout the day. The active agents constituting the treatment may be administered simultaneously, either in a combined dosage form or in separate dosage forms intended for substantially simultaneous oral administration. The active agents constituting the treatment may also be administered sequentially, with either active ingredient being administered by a regimen requiring two-step ingestion. Thus, the regimen may require sequential administration of the active agents, with separate active agents being ingested at intervals. The period between multiple ingestion steps may range from a few minutes to as long as about 72 hours, depending on the properties of each active agent, such as the potency, solubility, bioavailability, half-life, and kinetic profile of the substance, as well as the age and condition of the patient. Whether administered simultaneously, substantially simultaneously, or sequentially, the active agents of the treatment may include a regimen requiring administration of one active agent by oral route and the other active agent by intravenous route. In one aspect, the embodiments described herein can provide therapeutic and / or nutritional benefits that have not been realized or obtained before, and thus can provide unexpected and surprising improved ability to use the composition.In some embodiments, the composition is formulated for intravenous administration, since it can produce more concentrated solutions.Whether the therapeutic active agents are administered by oral or intravenous routes, separately or together, each such active agent is included in a suitable pharmaceutical formulation consisting of pharma- ceutically acceptable excipients, diluents or other formulation components.

[0082] In certain embodiments, the combination compositions disclosed herein are administered to a subject as NK3 antagonists. In certain embodiments, the compositions described herein are administered to a subject to treat, ameliorate, prevent, or reduce the effects of polycystic ovarian syndrome. In certain embodiments, the compositions described herein are administered to a subject to support and / or maintain healthy levels of NK3 antagonism. In certain embodiments, the compositions described herein are administered to a subject to treat, ameliorate, prevent, or reduce the effects of female infertility, hirsutism, acne, obesity, chronic anovulation, metabolic syndrome, type II diabetes, and combinations thereof. In certain embodiments, the compositions described herein are administered to support and / or maintain healthy female fertility. In some embodiments, the compositions described herein are administered in combination with a metabolic regulator such as metformin. In certain embodiments, the compositions described herein are administered to a subject to treat, ameliorate, prevent, or reduce the effects of cardiovascular disease and / or hypertension. In certain embodiments, the compositions described herein are administered to a subject to support and / or maintain healthy stress levels. 2 The compositions described herein are administered to a subject to treat, ameliorate, prevent or reduce the effects of polycystic ovary syndrome in a woman who has a blood sugar level greater than 100 mg / kg and has been identified as having polycystic ovary syndrome. In some embodiments, the compositions described herein are administered to a subject in combination with luteinizing hormone (LH) to treat, ameliorate, prevent or reduce the effects of one or more of the conditions described herein. In some embodiments, the compositions described herein are administered to a subject to treat, ameliorate, prevent or reduce the effects of hot flashes. In some embodiments, the compositions described herein are administered to a menopausal woman to maintain healthy levels of hot flashes, i.e., to reduce the number, frequency and / or severity of hot flashes.

[0083] Without being bound to any particular theory, it is believed that the compositions and / or dietary supplements disclosed herein act as antagonists by targeting the signaling pathways associated with menopause. It is believed that menopause-related symptoms are characterized by and are caused by increased secretion of LH and follicle-stimulating hormone (FSH) from the pituitary gland. It is believed that increased secretion of LH and FSH is mediated by increased secretion of gonadotropin hormone-releasing hormone (GnRH), which is caused by increased signaling of kisspeptin and NKB. Therefore, it is believed that antagonists can reduce increased secretion of GnRH, and ultimately secretion of LH and FSH, by blocking and / or limiting increased signaling of kisspeptin and NKB in their associated pathways. It is believed that reducing secretion of LH and FSH can treat, prevent, improve, and / or reduce the effects associated with menopause-related symptoms.

[0084] In some embodiments, the compositions described herein are administered to a subject to treat, ameliorate, prevent, or reduce the effects of mental, psychotic, and / or neuropsychiatric disorders, such as schizophrenia, aging-related cognitive decline, dementia, depression, and Alzheimer's. In some embodiments, the compositions described herein are administered to support and / or maintain healthy cognitive function. In certain embodiments, the compositions described herein are administered to a subject to treat, ameliorate, prevent, or reduce the effects of neuroinflammation. In some embodiments, the compositions described herein are administered in combination with an antipsychotic, including but not limited to aripiprazole, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, haloperidol, osanetant, and / or talnetant. In some embodiments, the compositions described herein are administered to a subject to treat, ameliorate, prevent, or reduce the effects of drug, nicotine, and / or alcohol addiction. In some embodiments, the compositions described herein are administered to a subject to reduce drug-seeking behavior.

[0085] In some embodiments, the compositions described herein are administered to a subject to treat, ameliorate, prevent, or reduce the effects of disorders associated with inflammation, including, but not limited to, central nervous system disorders (e.g., anxiety, psychosis, movement and convulsive disorders, and Parkinson's), respiratory and pulmonary inflammatory disorders, skin disorders and itch, gastrointestinal disorders, kidney and bladder disorders, inflammatory bowel disease, eating disorders, and chronic pain. In certain embodiments, the curcumin compositions are administered to treat hormonal changes.

[0086] As used herein, "identifying" refers to detecting or selecting a subject from a population of potential subjects, e.g., establishing that a particular subject has a certain characteristic or feature. "Identifying" may include, for example, self-identification, self-diagnosis, and diagnosis by a medical professional.

[0087] As used herein, the terms "prophylactic treatment," "prevent" or "preventing" can refer to treating a subject who does not yet exhibit symptoms of the disease or condition, but who is susceptible to or at risk for a particular disease or condition, whereby treatment reduces the likelihood that the patient will develop the disease or condition. A "disorder" is any condition that would benefit from treatment with the compositions described herein.

[0088] As used herein, the terms "treating", "treatment" and the like are used generally to refer to obtaining a desired pharmacological and physiological effect, and can also refer to a nutritional or nutrient enhancing effect, the scope and meaning of which will be apparent to one of skill in the art based on the context in which these terms are used. The effect may be prophylactic, in that it prevents or partially prevents a disease, condition, or state thereof, and / or it may be therapeutic, in that it partially or completely cures a disease, condition, symptom, or adverse effects caused by a disease. As used herein, the term "treatment" encompasses any treatment of a disease in a mammal, particularly a human, including (a) preventing the onset of a disease in a subject predisposed to, but not diagnosed as, suffering from the disease; (b) arresting the disease or its progression; or (c) relieving the disease, causing regression of the disease and / or its symptoms, conditions, and co-morbidities. The terms "optimal" or "healthy" and the like may be used to refer to a physiological amount of NK3 activity in a mammal, and administration of the compositions described herein may be administered to a mammal that may not be suffering from a disease associated with NK3 activity or may not exhibit symptoms of such a disease, but may be administered to antagonize NK3 in conjunction with other physiological results as described herein.

[0089] As used in the claims that follow and throughout this disclosure, the phrase "consisting essentially of" is meant to include any components recited after the phrase, and is limited to other components that do not interfere with or contribute to the activity or action set forth in the disclosure for the recited components. Thus, the phrase "consisting essentially of" indicates that the recited components are required or essential, but other components are optional and may or may not be present depending on whether they affect the activity or action of the recited components. For example, the use of a composition "consisting essentially of" for the treatment of a particular disease or disorder, or for the maintenance of a health condition, excludes other ingredients that would materially alter the intended outcome of the curcumin composition.

[0090] In this specification, the meaning of the term "hot flash" is immediately apparent to those skilled in the art. The cause of hot flash is understood by those skilled in the art to refer to sudden warm sensations, usually most intense over the face, neck and chest, and profuse sweating, most commonly caused by menopause. However, the compositions described herein can also be administered to treat, improve, prevent or reduce the effects of hot flashes that are not caused by menopause.

[0091] As used herein, a composition that "substantially" comprises a compound means that the composition comprises greater than about 80% by weight, more preferably greater than about 90% by weight, even more preferably greater than about 95% by weight, and most preferably greater than about 98% by weight of the compound.

[0092] The terms "pharmaceutical formulation", "formulation", "composition" and the like can refer to preparations that are in such a form as to effect the biological activity of the active ingredient and thus may be administered to a subject for therapeutic use in conjunction with the use of dietary supplements. The meaning of these terms will be clear to one of skill in the art based on the context in which they are used.

[0093] As used herein, a "therapeutically effective amount" includes within its meaning a compound active ingredient or a composition comprising the same for use in the embodiments disclosed herein in a non-toxic amount sufficient to obtain the desired therapeutic effect. Similarly, as used herein, an "effective amount" or "effective amount" includes within its meaning a compound active ingredient or a composition comprising the same in a non-toxic amount sufficient to obtain the desired therapeutic effect. A "therapeutically effective amount" or "effective amount" includes an amount of compound not obtained from a standard diet but requiring supplementation and dosing as described herein. The exact amount of active ingredient disclosed herein required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular substance being administered, the weight of the subject, and the mode of administration. Thus, it is not always possible to define an exact "effective amount". However, for any given case, the appropriate "effective amount" may be determined by one of skill in the art in view of the disclosure contained herein. In some embodiments, a therapeutically effective amount may include a dosing regimen. For example, a therapeutically effective amount may include about 100 mg of a curcumin composition taken orally daily for 14 consecutive days. In some aspects, a therapeutically effective amount may comprise about 100 mg of the composition taken orally daily for 30 consecutive days. The composition comprising the composition may comprise, for example, 0.1 to 1000 g of the composition.

[0094] As used herein, the terms "synergy," "synergistic," "synergistic," and the like are used generally to refer to a therapeutic efficacy of a composition that is at least equal to the sum of the efficacy of the individual components of the composition administered separately. "Synergy," "synergistic," "synergistic," and the like may also refer to a therapeutic efficacy of a composition that is greater than the sum of the efficacy of the individual components of the composition administered separately, the scope and meaning of which will be apparent to one of skill in the art based on the context in which these terms are used.

[0095] As used herein, disclosure of "ratios" of compounds and compositions corresponds to the ratio provided in terms of the mass of the components present in that ratio.

[0096] As used herein, the term "pharmaceutically acceptable solvent" can refer to water, water for injection, a physiologically compatible aqueous buffer solution, or an aqueous solution containing a physiologically compatible organic solvent. A non-exhaustive list of pharmaceutically acceptable solvents is provided by the U.S. Department of Health and Human Services, Food and Drug Administration, in "Guidance for Industry: Q3C Impurities: Residual Solvents," December 1997 or its latest issue.

[0097] As used herein, the term "bioavailability" refers to the amount of a substance that is absorbed in the intestine and ultimately available for biological activity in the tissues and cells of a subject.

[0098] As used herein, the term "enhancing bioavailability" and the like is used to refer to obtaining a desired pharmacological and / or physiological effect that antagonizes NK3 that is not naturally occurring and is absorbed from the intestine or taken up by tissues and cells following administration of the composition to a mammal. The effect may be prophylactic in that it prevents or partially prevents the occurrence, risk or severity of an adverse symptom or condition caused by or associated with the absence of the therapeutic agent.

[0099] As used herein, the term "excipient material" refers to any compound that is part of the formulation that is not the active ingredient, i.e., has no relevant biological activity, and is added to the formulation to provide certain characteristics to the dosage form including, for example, providing protection of the active ingredient from chemical degradation, facilitating removal of the tablet or caplet from the device in which it is formed, etc.

[0100] For purposes of this disclosure, a warm-blooded animal is a member of the animal kingdom, including, but not limited to, mammals and birds. In certain embodiments described herein, a mammal may be, for example, but not limited to, a horse, dog, or cat. The most preferred mammal of the present application is a human.

[0101] In order to provide a more concise description, some of the quantitative expressions given herein are not qualified by the term "about". Whether or not the term "about" is explicitly used, it is understood that all amounts given herein are meant to refer to the actual given value, and also to refer to the approximation of such given value that can be reasonably estimated based on the person skilled in the art, including the approximation resulting from the experimental and / or measurement conditions of such given value.

[0102] Although the invention has been described in some detail for purposes of clarity and understanding, it will be understood that various changes in form and detail may be made therein without departing from the true scope of the invention. EXAMPLES

[0103] Example 1 method The NK3 antagonist activity of the compositions disclosed herein was examined with human NK3 receptors expressed in transfected CHO cells. Antagonist activity was demonstrated by the inhibition of neurokinin B (NKB, a potent NK3 agonist)-induced cytoplasmic Ca2+ expression using a fluorescent detection method. 2+ This was determined by measuring the effect on ion mobilization. The results of administration of several components to transfected CHO cells are shown in Figures 1A-1C and further described below.

[0104] Experimental protocol CHO cells were suspended in DMEM buffer (Invitrogen) supplemented with 0.1% FCSd and then cultured at 3 × 10 4 Cells / well were distributed in a microplate. A fluorescent probe (Fluo4 Direct, Invitrogen) was mixed with probenecid in HBSS buffer (Invitrogen) supplemented with 20 mM HEPES (Invitrogen), pH 7.4, and then added to each well and equilibrated with the cells at 37°C for 60 min, followed by 22°C for 15 min.

[0105] The assay plate was then placed in a microplate reader (CellLux, PerkinElmer) used for the addition of the test items, the curcumin extracts specified in this specification or HBSS buffer, followed (5 min later) by the addition of 1 nM [MePhe7]-NKB or HBSS buffer (control). Free cytosolic Ca was then measured. 2+ The change in fluorescence intensity, which varies proportionally with ion concentration, was determined. The standard reference antagonist was SB 222200, which was tested at various concentrations to generate concentration-response curves from which IC50 values ​​were calculated.

[0106] The results are shown in Figures 1A-1C as percent inhibition of the control response to 1 nM [MePhe7]-NKB following administration of the curcumin, green tea extract, and phycocyanin compositions described herein, respectively. Figures 1A-1C show the excellent and unexpected NK3 inhibition, expressed as IC50 (μg / mL), obtained by administration of various compounds including the curcumin (Figure 1A), green tea extract (Figure 1B), and phycocyanin (Figure 1C) compositions, which were 2.92 μg / ml and 16.9 μg / ml, respectively, with no IC50 value obtained for the phycocyanin composition.

[0107] Example 2 method In vivo experiments were conducted to measure hypothalamic levels of NK3 and evaluate the efficacy of curcumin compositions, green tea extract compositions, phycocyanin compositions and their combinations as NK3 antagonists.

[0108] Experimental procedure Female Wistar rats were obtained from Japan SLC Inc. (Shizuoka, Japan). Eight-week-old rats were ovariectomized or sham-operated (control) under isoflurane anesthesia. All animals were housed individually under clean conditions with controlled temperature, humidity, and light (12-h light-dark cycle) and were provided with standard commercial diet and water ad libitum. All animal experimental procedures were approved by the Institutional Animal Care and Use Committee of Tsukuba Research Center of Astellas Pharma Inc., which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. Animals were handled and cared for in accordance with the Guide for the Care and Use of Laboratory Animals.

[0109] Four weeks after surgery, the rats were randomly divided into six groups: sham-operated rats treated with a vehicle consisting of 0.5% methylcellulose solution (C); ovariectomized rats treated with a vehicle consisting of 0.5% methylcellulose solution (OVX); ovariectomized rats treated with a curcumin composition as described in the specification at 600 mg HED (OVX+CL); ovariectomized rats treated with a green tea extract composition as described in the specification at 300 mg HED (OVX+EGCG); ovariectomized rats treated with a phycocyanin composition as described in the specification at 100 mg HED (OVX+P); and ovariectomized rats treated with a combination composition as described in the specification (OVX+CL+EGCG+P) including a curcumin composition as described in the specification at 600 mg HED, a green tea extract composition as described in the specification at 300 mg HED, and a phycocyanin composition as described in the specification at 100 mg HED. Vehicle or active drug was administered for 8 days.

[0110] Body weight and food intake were measured twice (before the first dose and on the last day of dosing). On the fifth day of repeated dosing, one small temperature data logger (Thermochron SL, KN Laboratories Inc., Osaka, Japan) was implanted into the abdominal cavity under isoflurane anesthesia, and another was attached to the skin of the tail using surgical tape and a homemade aluminum protector to prevent detachment. On the seventh day of repeated dosing, core, skin, and room temperatures were measured every 30 min for 24 h. Two to five hours after the final drug administration (10:00–14:00), blood samples were collected from the abdominal vena cava under isoflurane anesthesia, and the uterus was isolated and weighed. Blood samples were centrifuged, and plasma was separated and stored at −80°C until assay. Blood samples were analyzed for (i) serum levels of glucose, triglycerides, cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), urea, creatinine, malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSHPx), antioxidant enzymes, curcuminoids, EGCG and phycocyanin extract; (ii) calcium (Ca), inorganic phosphorus (P) and alkaline phosphatase (ALP); and (iii) plasma hormone levels such as estradiol, LH, FSH, progesterone and testosterone according to methods known in the art.

[0111] Brain tissue was analyzed to assess the levels of kisspeptin, NKB, GnRH, transient receptor potential cation channel subfamily V member 1 (TrpV1) and protein c-fos. Brain tissue was embedded in paraffin, and hypothalamic sections (3 μm thick) containing MnPO were prepared according to the rat brain atlas (Paxinos and Watson, 2007) and standard procedures. After deparaffinization, sections were incubated with Immunosaver (Nisshin EM Co., Ltd., Tokyo, Japan) for antigen retrieval at 100°C for 15 min, and then incubated with 3% hydrogen peroxide to block endogenous peroxidase. Samples were incubated with 1% bovine serum albumin for 20 min at room temperature, and then incubated with anti-kisspeptin, NKB, GnRH, TrpV1 or c-fos monoclonal antibodies (diluted 1:100) at 4°C overnight. Samples were then processed with the DAKO EnVision System (Agilent Technologies, Santa Clara, CA, USA). ImmPACT DAB (Vector Laboratories, Inc., Burlingame, CA, USA) was used for color development. Densitometric analysis of relative intensities of Western blot bands to controls was performed with β-actin normalization to ensure equal protein loading. Blots were repeated at least three times (n=3) and representative blots are shown. ANOVA and Tukey's post-hoc tests were performed for statistical comparisons (p<0.05). Data are presented as mean±standard deviation. Different lowercase letters (a-d) above the data columns indicate statistical differences between groups.

[0112] Quantitative assessment of c-Fos-positive neurons (stained reddish brown) was performed using a computer-controlled image analysis system (WinROOF Ver. 6.0; Mitani Corp., Fukui, Japan) that automatically counted the number of reddish brown (c-Fos-positive) cells in the MnPO by light microscopy at 100x magnification (pre-entering the wavelength of optimal color and approximate cell size).

[0113] The results of hypothalamic levels of NKB from Example 2 are shown in Figure 2. Figure 2 shows a remarkable and unexpected result. As expected, the hypothalamic NKB levels of ovariectomized rats (OVX) were the highest. Surprisingly, the individual compositions of the present disclosure significantly reduced NKB levels below those of OVX rats. Unexpectedly, the combination composition described herein (OVX+CL+EGCG+P) restored NKB levels to the levels of non-ovariectomized mice (C) treated with saline.

[0114] Example 3 method An in vivo experiment was conducted to measure hypothalamic levels of NKB to evaluate the efficacy of the combination composition of the present disclosure, including the curcumin extract composition, green tea extract composition and phycocyanin composition of the present disclosure, as an NK3 antagonist.

[0115] Experimental procedure Example 3 is the same procedure and analysis as described in Example 2. In Example 3, the amounts of the curcumin composition, green tea extract composition and phycocyanin composition of the present disclosure in the various combination compositions disclosed herein were varied. In Example 3, the experimental groups were sham-operated rats treated with a vehicle consisting of 0.5% methylcellulose solution (C); ovariectomized rats treated with a vehicle consisting of 0.5% methylcellulose solution (OVX); ovariectomized rats treated with 600 mg HED of a curcumin composition, 300 mg HED of a green tea extract composition, and 100 mg HED of a phycocyanin composition (OVX+CL1+EGCG1+P); ovariectomized rats treated with 450 mg HED of a curcumin composition, 450 mg HED of a green tea extract composition, and 100 mg HED of a phycocyanin composition (OVX+CL2+EGCG2+P); and ovariectomized rats treated with 720 mg HED of a curcumin composition, 180 mg HED of a green tea extract composition, and 100 mg HED of a phycocyanin composition (OVX+CL3+EGCG3+P). Vehicle or active drug was administered for 8 days. Data are presented as mean ± standard deviation. The different lowercase letters (a to d) above the data columns indicate statistical differences between groups.

[0116] The results of hypothalamic levels of NKB according to Example 2 are shown in Figure 3. Figure 3 shows a remarkable and unexpected result. As expected, the hypothalamic levels of ovariectomized rats (OVX) were the highest. Surprisingly, all the combination compositions evaluated significantly reduced NKB levels below those of OVX rats.

Claims

1. A combination composition comprising a curcumin composition, a green tea extract composition and a phycocyanin composition.

2. 2. The combination composition of claim 1, comprising said curcumin composition, said green tea extract composition and said phycocyanin composition in a synergistic ratio.

3. 3. The combination composition of claim 2, wherein the synergistic ratio of the curcumin composition, the green tea extract composition, and the phycocyanin composition is about 6:3:1, respectively.

4. 3. The combination composition of claim 2, wherein the synergistic ratio of the curcumin composition, the green tea extract composition, and the phycocyanin composition is about 4.5:4.5:1, respectively.

5. 3. The combination composition of claim 2, wherein the synergistic ratio of the curcumin composition, the green tea extract composition, and the phycocyanin composition is about 7.2:1.8:1, respectively.

6. 2. The combination composition of claim 1, wherein the amount of the curcumin composition is from about 100 mg to about 750 mg.

7. 2. The combination composition of claim 1, wherein the amount of the green tea extract composition is from about 100 mg to about 500 mg.

8. 2. The combination composition of claim 1, wherein the amount of the phycocyanin composition is about 100 mg.

9. 10. The combination composition of claim 1, wherein when the combination composition is administered to a subject, administration of the combination composition treats, ameliorates, prevents or alleviates symptoms associated with menopause in the subject.

10. 2. The combination composition of claim 1, wherein when the combination composition is administered to a subject, administration of the combination composition treats, ameliorate, prevent or reduce the effects of hot flashes, maintains a healthy level of hot flashes, or both in the subject.

11. The combination composition of claim 1 , wherein the combination composition is formulated as a dietary supplement or a pharmaceutical.

12. 2. The combination composition of claim 1, wherein the curcumin composition comprises a compound selected from the group consisting of diferuloylmethane, demethoxycurcumin, bis-demethoxycurcumin, tetrahydrocurcumin, dihydrocurcumin, hexahydrocurcumin, octahydrocurcumin, and any combination thereof.

13. 2. The combination composition of claim 1, wherein the green tea extract comprises a compound selected from the group consisting of epigallocatechin gallate, epicatechin, epigallocatechin, epicatechin gallate, and any combination thereof.

14. 1. A method for treating, ameliorating, preventing or alleviating symptoms associated with menopause in a subject, the method comprising: Identifying the subject as exhibiting or in the future exhibiting symptoms associated with menopause; and administering to said subject a combination composition comprising a neurokinin 3 (NK3) antagonist. A method comprising:

15. 15. The method of claim 14, wherein the NK3 antagonist is selected from the group consisting of a curcumin composition, a green tea extract composition, a phycocyanin composition, and any combination thereof.

16. 16. The method of claim 15, wherein the combination composition comprises the curcumin composition, the green tea extract composition and the phycocyanin composition in a synergistic ratio.

17. 17. The method of claim 16, wherein the amount of the curcumin composition is from about 100 mg to about 750 mg.

18. 17. The method of claim 16, wherein the amount of the green tea extract composition is from about 100 mg to about 500 mg.

19. 17. The method of claim 16, wherein the amount of the phycocyanin composition is about 100 mg.

20. 1. A method for treating, ameliorating, preventing or reducing the effects of a hot flash in a subject, comprising: Identifying the subject as being affected or likely to be affected by hot flashes; and administering to said subject a combination composition comprising an NK3 antagonist. A method comprising:

21. 21. The method of claim 20, wherein the NK3 antagonist is selected from the group consisting of a curcumin composition, a green tea extract composition, a phycocyanin composition, and any combination thereof.

22. 22. The method of claim 21, wherein the combination composition comprises the curcumin composition, the green tea extract composition and the phycocyanin composition in a synergistic ratio.

23. 23. The method of claim 22, wherein the amount of the curcumin composition is from about 100 mg to about 750 mg.

24. 23. The method of claim 22, wherein the amount of the green tea extract composition is from about 100 mg to about 500 mg.

25. 23. The method of claim 22, wherein the amount of the phycocyanin composition is about 100 mg.

Citation Information

Patent Citations

  • Anti-depressant medicine, anti-climacteric medicine, senile dementia medicine, alzheimer'S dementia medicine

    JP2003113117A

  • Composition for producing adjuvant for cancer patients receiving chemotherapy

    JP2015051970A

  • Composition for preventing, alleviating, improving, or treating female hormone regulation disorder syndrome or symptoms comprising green tea extract which has modified amounts of ingredients

    JP2021138686A

  • A composition for the treatment or prevention of climacteric disorder comprising an extract of cheongkukjang

    KR1020080095581A

  • Composition for prevention and / or treatment of cancer

    US20080260695A1